Lenalidomide after autologous stem cell transplantation prolongs survival in multiple myeloma

Accounting for %15 of hematological malignancies, meaning blood and bone marrow cancers, multiple myeloma, is a cancer originating from the immune system's plasma cells. With a median diagnosis age of 72, it progresses quite slowly, so causes no early symptoms and is usually diagnosed at an advanced stage.
A cancer of older age, multiple myeloma's first symptoms include anemia and frequent infections due to the bone marrow's inability to produce blood and defense cells, as well as small areas of bone loss (lytic lesions), most commonly in lumbar spinal bones, and bone pain. These complaints can also occur in many other conditions in older people. At more advanced stages, multiple myeloma may manifest as kidney failure.
In multiple myeloma treatment, a series of sequential and combined chemotherapy regimens is initially given to reduce myeloma cancer cell numbers as much as possible. Chemotherapy prepares for subsequent autologous stem cell transplantation and improves its success. Transplantation is attempted in all patients whose general condition permits. Thus, standard treatment is chemotherapy followed by autologous stem cell transplantation. Nevertheless, most patients experience recurrence, called relapse, within 2 years. Therefore, after transplantation, treatments reducing recurrence likelihood or at least substantially delaying it, called maintenance treatments , are being investigated.
A study published on 25 July in the Journal of Clinical Oncology, the most closely followed scientific publication in cancer, showed that using Lenalimomid (trade names Revlimid and Rivelime) as maintenance after autologous stem cell transplantation in multiple myeloma controlled cancer much better and significantly prolonged overall survival.
Lenalidomide was already known to prolong progression-free survival, meaning time cancer remains controlled, in multiple myeloma. Its contribution to overall survival, however, was unclear. Researchers therefore conducted a comprehensive, valuable meta-analysis collecting and reassessing data from previous studies.
This meta-analysis analyzed cancer-control and overall-survival data from 1208 multiple myeloma patients. After autologous transplantation, they were divided into two groups: the lenalidomide group with 605 patients, and placebo (inactive medicine) and observation with 603 patients.
According to the research results;
- Median cancer-control duration was 52.8 months with lenalidomide maintenance, compared with 23.5 months in the placebo and observation group.
- Patients were followed for approximately 80 months. Overall survival could not yet be determined in the lenalidomide group because most were still alive at analysis, while median overall survival in the placebo and observation group was 86 months.
In conclusion, this meta-analysis reinforces maintenance lenalidomide's cancer-control success after autologous stem cell transplantation in multiple myeloma by showing it also significantly prolongs overall survival.
Sources
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Journal of Clinical Oncology - published online before print July 25, 2017.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.